Transaction · 0001549595-25-000024

Ring Christine

Ring Christine, CLO, reported an open-market or private sale at Nurix Therapeutics, Inc. involving 2929.000000 shares for an estimated $58014.12. Reported holdings after the transaction were 32829.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SCLO
NRIXNurix Therapeutics, Inc.
Filing timeJan 31
Trade dateJan 30, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

NRIX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
NRIX since 2025-01-31Filed 581 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001549595-25-000024
Common Stock
Transaction date
Jan 30, 2025
Filed Jan 31, 2025, 12:53 AM · 1d delay
Shares
2.92k sh
$1.98k per share
Estimated value
-$5.80M
Computed from shares × price
Holdings after
32.8k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership Repeat Seller
+10score
Filing-only score

+10

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Legal Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). T…

  2. F2

    Represents the weighted average sale price. The lowest price at which shares were sold was $19.28 and the highest price at which shares were sold was $20.275. The Reporting Person undertakes to provid…

  3. F3

    Represents the weighted average sale price. The lowest price at which shares were sold was $20.28 and the highest price at which shares were sold was $20.39. The Reporting Person undertakes to provide…

  4. F4

    Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

  5. F5

    The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to…

  6. F6

    RSUs do not expire; they either vest or are canceled prior to the vest date.

  7. F7

    The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the…

  8. F8

    The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the…

Original filing · 0001549595-25-000024
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

NRIX